InvestWiser

Senzime AB

SEZINasdaq StockholmHealthcareMarket value 526 m SEK
3.35SEK −0.4%
last day · Price as of 18 November 2026

The answer first

Does Senzime beat the market?

No, Senzime has not beaten the market over the last year.

Senzime−33.2%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 18% of Nordic stocks

    • Quality73
    • Value14
    • Trend14

    No. 136 of 195 in healthcare

Max for seven days

Follow Senzime with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Senzime

From today, at a price of 3.35 SEK. Write why you follow Senzime, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Senzime

Your first answer is free, no account needed.

Do you own Senzime, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Senzime and a few more. Free, no card.

Past year against the exchange and Super Stock
Senzime−33.2%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Senzime has fallen 33.2% over the past year, including dividends.
  • Overall, Senzime ranks better than 18% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 82.2%. The price is 87.2% below its peak now.

What do analysts think of Senzime?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

18

Quality, value and trend together. Better than 18% of Nordic stocks.

No. 136 of 195 in healthcare

Quality73
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 75 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.11
  • Asset turnoverSales divided by everything the company owns0.34
  • Return on equityProfit divided by equity−38.5%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value14
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 122 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity2.0
  • P/SPrice divided by sales4.9
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend14
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 146 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−13.0%
  • 6 months−26.9%
  • 9 months−33.1%
  • 12 months−33.2%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+19.0%
3 years, per year
−20.6%
5 years, per year
−29.7%
10 years, per year
−3.6%
Largest fall, 3 years
−82.2%
From a peak to the bottom
From the peak now
−87.2%
How far the price is from the peak
Volatility, 1 year
59.5%
How much the price swings over a year
Beta, 1 year
0.38
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Senzime

6 funds we follow own Senzime. The share is how much of the fund the stock makes up.

  • Sweden6

From the funds' latest known holdings.

About Senzime

Senzime AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 59 employees.

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue's opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe.

See the full analysis of Senzime.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market